跳至主要内容
临床试验/NCT02675335
NCT02675335撤回3 期

Accelerated Wound Healing in Diabetic Ulcers by Sitagliptin

Wolfgang-Michael Franz0 个研究点开始时间: 2016年3月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
撤回
发起方
主要终点
mean ulcer size after a treatment period of 12 weeks

研究概览

简要总结

The purpose of the study is to test the effect of Sitagliptin on the healing of stable, nonhealing diabetic foot ulcers. This is a randomized placebo-controlled Trial.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 100 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • type 2 diabetes mellitus
  • at least 1 diabetic foot ulcer with a size between 1 and 20 sqcm
  • stable size of the foot ulcer for at least 2 weeks
  • HbA1c <= 8% under Treatment with Insulin, metformin, sulfonylureas, SGLT2 Inhibitors, glinides or glitazones

排除标准

  • local purulent signs of Inflammation at ulcer site
  • planned interventional or surgical therapy of a macro vessel disease of the lower limb
  • glomerular filtration rate <30ml/min
  • liver cirrhosis CHILD B or C
  • pregnancy, lactation
  • allergy against Sitagliptin
  • ongoing treatment with dipeptidyl peptidase 4 (DPP4) Inhibitors

研究组 & 干预措施

Sitagliptin

Active Comparator

Sitagliptin tablets, 100mg per day, 12 weeks treatment

干预措施: Sitagliptin (Drug)

Placebo

Placebo Comparator

Placebo tablets, 1 tablet per day, 12 weeks treatment

干预措施: Placebo (Drug)

结局指标

主要结局

mean ulcer size after a treatment period of 12 weeks

时间窗: 12 weeks

次要结局

未报告次要终点

研究者

发起方
Wolfgang-Michael Franz
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Wolfgang-Michael Franz

Professor

Medical University Innsbruck

相似试验